AOD-9604

Mechanism

AOD-9604 is residues 176–191 of human growth hormone — the C-terminal fragment that contains hGH's lipolytic activity. When researchers cleaved hGH into functional regions, this fragment retained the fat-mobilization effect while shedding the glucose-disrupting and IGF-1-elevating properties of the full molecule. The mechanism involves stimulation of lipolysis in adipose tissue through pathways adjacent to β3-adrenergic signaling, increasing fatty acid release from fat cells without the metabolic disruption that comes with full GH.

The narrowness of the target is both the selling point and the honest limitation. AOD-9604 does not build muscle, does not raise IGF-1 meaningfully, and does not disrupt insulin sensitivity — making it one of the few body-composition peptides viable for users who need to stay metabolically clean (diabetic-adjacent users, those on GLP-1 therapy, athletes under hormone-panel scrutiny). The trade-off is that the lipolytic effect, while real and measurable in studies, is modest. It accelerates the process; it does not replace the caloric math.

Half-life is approximately 20 minutes, so dosing must be timed precisely — fasted state, ideally followed by cardio, to maximize the lipolytic window before fatty acid reuptake occurs. The short half-life also means no accumulation and rapid clearance, making it easy to cycle in and out without transition management.

Typical protocol

• Starter: 250 mcg SC fasted morning, once daily. Follow immediately with fasted cardio (20–30 min) to capitalize on the mobilized fatty acids.
• Advanced: 500 mcg SC fasted AM × 6–10 week cycles. In the Recomp Stack it runs alongside CJC + ipamorelin at approximately 300 mcg per dose.
• Cycle length: 6–10 weeks on / 2 weeks off. Diminishing returns appear past week 8 as adipose receptor sensitivity adapts.
• Reconstitution: 5 mg vial + 2 mL BAC water → 2.5 mg/mL. 10 IU on a U-100 insulin syringe = 0.1 mL = 250 mcg.

Who it's for

Fat loss, specifically users who want GH-axis lipolytic drive without GLP-1-scale appetite suppression or full GH's glucose disruption. Works best in an already-lean user targeting stubborn adipose — the last 5–10 lbs on an otherwise clean body composition. Less suited to users significantly above their target weight, where caloric intervention and appetite management will move the needle far more than direct lipolytic stimulation.

Stacks well with

• cjc 1295 dac 2mg — GHRH support amplifies the lipolytic window by elevating overall GH-axis activity alongside AOD's direct action.
• ipamorelin 5mg — GH pulse pairing that keeps the anabolic side of the axis active during a cut, preserving lean mass.
• recomp stack cjc ipamorelin aod — pre-bundled recomp stack combining all three.
• semaglutide 5mg — different mechanism (appetite suppression vs. direct lipolysis); complementary on demanding cuts where both caloric reduction and direct fat mobilization are wanted.

Watch-outs

• Effect is real but modest. Expect incremental improvement in fat loss rate, not GLP-1-scale weight reduction. Set expectations accordingly.
• Requires an actual caloric deficit. AOD-9604 accelerates lipolysis within that deficit — it does not create the deficit itself.
• Diminishing returns emerge past week 8. Cycle off before the effect flattens rather than running continuously and wondering why it stopped working.